NNVC : Summary for NanoViricides, Inc. NEW - Yahoo Finance

U.S. Markets closed

NanoViricides, Inc. (NNVC)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
1.23+0.02 (+1.65%)
At close: 4:06PM EDT
People also watch
BTXISCOGALTECTEAVXL
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.21
Open1.22
Bid1.15 x 1000
Ask1.25 x 800
Day's Range1.22 - 1.29
52 Week Range1.03 - 2.04
Volume127,694
Avg. Volume67,785
Market Cap77.27M
Beta0.25
PE Ratio (TTM)-6.15
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles
    PR Newswire3 days ago

    NanoViricides CEO Dr. Seymour to Present an Update on the Company at The Planet Microcap Showcase - 2017 in Las Vegas; Company Says it is Close to Declaring a Clinical Candidate for the Treatment of Shingles

    SHELTON, Conn., April 26, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), reports that Eugene Seymour, MD, MPH, CEO, will present information about the Company and its progress towards human trials at the Planet Microcap conference at the Planet Hollywood Hotel. NanoViricides, Inc. is a global leader developing antiviral nanomedicines for the treatment of a number of different viral infections. The Company is currently focused on developing its broad spectrum anti-herpesvirus drug candidates.

  • PR Newswire2 months ago

    NanoViricides Files Quarterly Report for Period Ending 2016-12-31

    SHELTON, Conn., Feb. 16, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), filed its quarterly report for its second quarter of financial year 2017 in a timely manner with the Securities and Exchange Commission on Tuesday, February 14th. NanoViricides reported that it had approximately $19.44 Million (M) of current assets (cash, cash equivalents, and prepaid expenses) as of December 31, 2016, the end of the reporting period. The net cash used in operating activities during this quarter was approximately $2.6 M. The Company's research and development (R&D) expenditure has increased as we advance towards human clinical trials.

  • Associated Press2 months ago

    NanoViricides reports 2Q loss

    On a per-share basis, the Shelton, Connecticut-based company said it had a loss of 3 cents. Losses, adjusted for non-recurring gains, were 4 cents per share. The company's shares closed at $1.17. A year ...